Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors at 5 institutions in 3 countries.
Rosa CatalanoDepartment of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.
Barbara AltieriDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany.ORCID 0000-0003-2616-3249
Anna AngelousiFirst Department of Internal Medicine, Laikon General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0003-0906-3617
Maura ArosioDepartment of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.ORCID 0000-0003-3988-3616
Francesca BraviDepartment of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.ORCID 0000-0003-0173-5319
Letizia CanuEndocrinology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy.ORCID 0000-0003-4995-8108
Giorgio A CrociPathology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0001-5979-7841
Mario DetomasDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany.ORCID 0000-0001-7864-6125
Emanuela EspositoDepartment of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.
Emanuele FerranteEndocrinology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0002-0556-7650
Stefano FerreroPathology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Carmina T FussDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany.
Gregory KaltsasFirst Department of Internal Medicine, Laikon General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Otilia KimpelDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany.
Laura-Sophie LandwehrDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany.ORCID 0000-0002-6315-4176
Michaela LuconiEndocrinology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy.ORCID 0000-0001-5186-064X
Valentina MorelliEndocrinology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0002-6716-3045
Gabriella NesiEndocrinology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy.ORCID 0000-0002-2614-944X
Emma NozzaDepartment of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.
Silviu SbieraDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany.ORCID 0000-0002-6271-5533
Andreea L SerbanEndocrinology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Cristina L RonchiInstitute of Metabolism and System Research, University of Birmingham, Birmingham B15 2TT, UK.ORCID 0000-0001-5020-2071
Giovanna MantovaniDepartment of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-9065-3886
Erika PeverelliDepartment of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-4424-7895
University of Milan · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITIstituto Nazionale di Documentazione Innovazione e Ricerca Educativa · ITNational and Kapodistrian University of Athens · GRUniversity of Birmingham · GB
Funding
Italian Association for Cancer Research IG 2021-25920Progetti di Ricerca di Interesse Nazionale (PRIN) 2017N8CK4K
6 · The paper itself
Abstract
The insulin-like growth factor 2 (IGF2) promotes cell growth by overactivating the IGF system in an autocrine loop in adrenocortical carcinomas (ACCs). The cytoskeleton protein filamin A (FLNA) acts as a repressor of IGF2 mitogenic signalling in ACC cells. The aims of this study were to test FLNA expression by immunohistochemistry in 119 ACCs and 26 adrenocortical adenomas (ACAs) and to evaluate its relationship with clinicopathological features and outcome in ACCs. We found that 71.4% of ACCs did not express FLNA, whereas FLNA absence was a rare event in ACAs (15.4%,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
High Filamin a Expression in Adrenocortical Carcinomas Is Associated with a Favourable Tumour Behaviour: A European Multicentric Study. · full record | Socratic